查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553491

莱姆病检测市场规模、份额、趋势分析报告：按技术、按测试、按样本、按最终用途、按地区、细分市场预测，2024-2030 年

Lyme Disease Testing Market Size, Share & Trends Analysis Report By Technology (IGRA Testing), By Testing (Serological Test, Nucleic Acid Test), By Sample (Blood, Urine), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10个工作天内

价格

莱姆病检测市场的成长与趋势：

Grand View Research, Inc.最新报告预测，到2030年，全球莱姆病检测市场规模预计将达到185.7亿美元，2024年至2030年复合年增长率为8.2%。

推动这一市场的主要因素是患病率不断上升、政府对医疗设施的支持政策以及莱姆病新诊断测试的推出。此外，蜱传疾病的日益普及进一步扩大了全球市场。例如，2022 年 8 月，美国健康与福利研究所报告称，莱姆病的盛行率在过去 15 年中显着增加，已成为全国关注的问题。

不断增加的政府倡议和预防措施将显着促进市场成长。例如，2022年7月，报导报道称，纽约州官员宣布，州长凯西·霍赫尔签署的一项新法律将增加对莱姆病和蜱传疾病的资助。这项两党措施将为各地创建一个自愿税收核对框，以支持莱姆病的教育、研究和预防工作。儘管莱姆病和蜱传疾病的发生率很高，但由于诊断测试的不准确，实际病例数据信要高得多。

意识和教育的提高进一步推动了市场的成长。向社区宣传预防策略和症状的公共卫生宣传活动正变得越来越普遍。这种认识的提高促使更多的人在出现与疾病相符的症状时寻求医疗护理，并增加了对可靠检测选择的需求。此外，针对医疗保健专业人员的教育措施正在为他们提供有关诊断和治疗最佳实践的资讯。

莱姆病检测市场报告亮点

  • 按技术划分，其他领域以 2023 年最大的销售份额 88.6% 引领市场。这些测试的广泛采用，由于其高特异性和敏感性而被认为是测试的黄金标准，对这一领域的成长做出了重大贡献。
  • 根据测试，血清学检测领域在 2023 年以 53.1% 的最高收益占有率引领市场。这些测试在市场上占据主导地位，因为它们在检测伯氏疏螺旋体抗体方面广泛可用、价格实惠、成熟且可靠。这使其成为医疗保健提供者和患者可靠且易于使用的选择。
  • 从样本来看，血液细分市场在 2023 年以 62.4% 的最大销售份额引领市场。这是透过 ELISA 和蛋白质印迹等血液检查进行的，可以有效检测针对伯氏疏螺旋体（引起莱姆病的细菌）的抗体。血液样本易于取得和处理，使其成为广泛诊断用途的实用选择。
  • 按最终用途划分，医院细分市场在 2023 年以 58.4% 的最大销售份额引领市场。首先，医院可以获得先进的技术和诊断工具，可以进行准确、及时的检测。大量医院患者（包括症状复杂且严重的患者）需要可靠的诊断服务，进一步增强了市场主导地位。
  • 2024年1月，DiaSorin宣布已于2023年12月向美国FDA提交了LIAISON LymeDetect测试。此测试与 QIAGEN 合作开发，使用 QIAGEN 专有的 QuantiFERON 技术、干扰素-Gamma 释放测定 (IGRA) 来检测 IgG、IgM 和 T 细胞介导的反应。这项新解决方案增强了 Diasolin 在美国市场的 Reazon 免疫诊断服务，标誌着我们与 QIAGEN 合作的一个重要里程碑。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章莱姆病检测市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 莱姆病检测市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 管道分析

第四章莱姆病检测市场：技术估算与趋势分析

  • 全球莱姆病检测市场：按技术分類的仪表板
  • 全球莱姆病检测市场：技术变迁分析
  • 全球莱姆病检测市场：按技术分類的收益
  • IGRA检查
  • 其他的

第五章莱姆病检测市场：透过测试进行估计和趋势分析

  • 全球莱姆病检测市场：按测试显示的仪表板
  • 全球莱姆病检测市场：测试变异分析
  • 测试收益
  • 血清学检测
  • 淋巴球转化试验
  • 尿液抗原检测
  • 萤光染色
  • 核酸检测

第六章莱姆病检测市场：样本估算与趋势分析

  • 全球莱姆病检测市场：按样本分類的仪表板
  • 全球莱姆病检测市场：样本变异分析
  • 按样本分類的收益
  • 血
  • 尿
  • 脑脊髓液
  • 其他的

第 7 章 莱姆病检测市场：依最终用途分类的估算与趋势分析

  • 全球莱姆病检测市场：依最终用途分類的仪表板
  • 全球莱姆病检测市场：最终用途的变异分析
  • 按最终用途分類的收益
  • 医院
  • 诊断实验室
  • 其他的

第 8 章莱姆病检测市场：按技术、样本、测试和最终用途进行的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第9章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业市场占有率分析
    • DiaSorin SpA
    • BIOMERIEUX
    • Oxford Immunotec
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific, Inc.
    • T2 Biosystems
    • IGeneX
    • Gold Standard Diagnostics
    • ZEUS Scientific
    • Trinity Biotech
Product Code: GVR-4-68040-419-8

Lyme Disease Testing Market Growth & Trends:

The global lyme disease testing market size is anticipated to reach USD 18.57 billion by 2030 and is projected to grow at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing prevalence, supportive government policies regarding healthcare facilities, and the introduction of new diagnostic tests for Lyme disease. In addition, the growing incidence of tick-borne diseases further expands the global market. For instance, in August 2022, the U.S. Fair Health Organization reported that Lyme disease has significantly increased in prevalence over the past 15 years, becoming a growing national concern.

Growing government initiatives and preventive measures significantly drive the market growth. For instance, in July 2022, an article titled "New laws seek to boost funding of Lyme disease research" highlighted that New York officials have increased funding for Lyme disease and tick-borne illnesses through a new law signed by Governor Kathy Hochul. This bipartisan measure will establish a voluntary tax check-off box to support education, research, and prevention efforts related to the disease in the region. Despite the high incidence of Lyme and tick-borne illnesses, it is believed that the actual number of cases is much higher due to inaccurate diagnostic testing.

Heightened awareness and education are further propelling market growth. Public health campaigns to educate communities about prevention strategies and symptoms have become increasingly prevalent. This growing awareness leads to more individuals seeking medical attention when they exhibit symptoms consistent with the disease, thereby driving demand for reliable testing options. Furthermore, educational initiatives targeting healthcare professionals ensure they remain informed about best practices for diagnosis and treatment.

Lyme Disease Testing Market Report Highlights:

  • Based on technology, the other segment led the market with the largest revenue share of 88.6% in 2023. The widespread adoption of these tests, considered the gold standard for testing due to their high specificity and sensitivity, significantly contributed to the growth of this segment
  • Based on testing, the serological test segment led the market with the largest revenue share of 53.1% in 2023. These tests dominated the market as they are widely available, affordable, established, and reliable in detecting antibodies against Borrelia burgdorferi. This makes them a trusted and accessible option for healthcare providers and patients
  • Based on sample, the blood segment led the market with the largest revenue share of 62.4% in 2023. This is due to the blood tests, such as ELISA and Western blot, which can effectively detect antibodies against Borrelia burgdorferi, the bacteria causing Lyme disease. Blood samples are also easy to obtain and handle, making them a practical choice for widespread diagnostic use
  • Based on end use, the hospital segment led the market with the largest revenue share of 58.4% in 2023. Firstly, hospitals can access advanced technology and diagnostic tools, enabling accurate & timely testing. The high hospital patient volume, including those with complex and severe symptoms, necessitates reliable diagnostic services, further driving their market dominance
  • In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN's proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Testing
    • 1.2.3. Sample
    • 1.2.4. End Use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Testing outlook
    • 2.2.3. Sample outlook
    • 2.2.4. End Use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Lyme Disease Testing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rise in prevalence of lyme disease
      • 3.2.1.2. Rising number of research programs for Lyme disease diagnosis
      • 3.2.1.3. Launch of new lyme diagnostic tests
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of awareness regarding testing
  • 3.3. Lyme Disease Testing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis

Chapter 4. Lyme Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Global Lyme Disease Testing Market: Technology Dashboard
  • 4.2. Global Lyme Disease Testing Market: Technology Movement Analysis
  • 4.3. Global Lyme Disease Testing Market by Technology, Revenue
  • 4.4. IGRA Testing
    • 4.4.1. IGRA Testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Others
    • 4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lyme Disease Testing Market: Testing Estimates & Trend Analysis

  • 5.1. Global Lyme Disease Testing Market: Testing Dashboard
  • 5.2. Global Lyme Disease Testing Market: Testing Movement Analysis
  • 5.3. Global Lyme Disease Testing Market Estimates and Forecasts, by Testing, Revenue (USD Million)
  • 5.4. Serological Test
    • 5.4.1. Serological Test market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. ELISA
      • 5.4.2.1. ELISA market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Western Blot
      • 5.4.3.1. Western blot market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Lymphocytic Transformation Test
    • 5.5.1. Lymphocytic transformation test market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Urine Antigen Testing
    • 5.6.1. Urine Antigen Testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Immunofluorescent Staining
    • 5.7.1. Immunofluorescent Staining market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Nucleic Acid Test
    • 5.8.1. Nucleic Acid Test market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lyme Disease Testing Market: Sample Estimates & Trend Analysis

  • 6.1. Global Lyme Disease Testing Market: Sample Dashboard
  • 6.2. Global Lyme Disease Testing Market: Sample Movement Analysis
  • 6.3. Global Lyme Disease Testing Market Estimates and Forecasts, By Sample, Revenue (USD Million)
  • 6.4. Blood
    • 6.4.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Urine
    • 6.5.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. CSF
    • 6.6.1. CSF market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Lyme Disease Testing Market: End Use Estimates & Trend Analysis

  • 7.1. Global Lyme Disease Testing Market: End Use Dashboard
  • 7.2. Global Lyme Disease Testing Market: End Use Movement Analysis
  • 7.3. Global Lyme Disease Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Diagnostic Laboratories
    • 7.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Lyme Disease Testing Market: Regional Estimates & Trend Analysis by Technology, Sample, Testing, and End Use

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Vendor Landscape
    • 9.2.1. List of key distributors and channel partners
    • 9.2.2. Key customers
    • 9.2.3. Key company market share analysis, 2023
    • 9.2.4. DiaSorin S.p.A
      • 9.2.4.1. Company overview
      • 9.2.4.2. Financial performance
      • 9.2.4.3. Product benchmarking
      • 9.2.4.4. Strategic initiatives
    • 9.2.5. BIOMERIEUX
      • 9.2.5.1. Company overview
      • 9.2.5.2. Financial performance
      • 9.2.5.3. Product benchmarking
      • 9.2.5.4. Strategic initiatives
    • 9.2.6. Oxford Immunotec
      • 9.2.6.1. Company overview
      • 9.2.6.2. Financial performance
      • 9.2.6.3. Product benchmarking
      • 9.2.6.4. Strategic initiatives
    • 9.2.7. Bio-Rad Laboratories, Inc.
      • 9.2.7.1. Company overview
      • 9.2.7.2. Financial performance
      • 9.2.7.3. Product benchmarking
      • 9.2.7.4. Strategic initiatives
    • 9.2.8. Thermo Fisher Scientific, Inc.
      • 9.2.8.1. Company overview
      • 9.2.8.2. Financial performance
      • 9.2.8.3. Product benchmarking
      • 9.2.8.4. Strategic initiatives
    • 9.2.9. T2 Biosystems
      • 9.2.9.1. Company overview
      • 9.2.9.2. Financial performance
      • 9.2.9.3. Product benchmarking
      • 9.2.9.4. Strategic initiatives
    • 9.2.10. IGeneX
      • 9.2.10.1. Company overview
      • 9.2.10.2. Financial performance
      • 9.2.10.3. Product benchmarking
      • 9.2.10.4. Strategic initiatives
    • 9.2.11. Gold Standard Diagnostics
      • 9.2.11.1. Company overview
      • 9.2.11.2. Financial performance
      • 9.2.11.3. Product benchmarking
      • 9.2.11.4. Strategic initiatives
    • 9.2.12. ZEUS Scientific
      • 9.2.12.1. Company overview
      • 9.2.12.2. Financial performance
      • 9.2.12.3. Product benchmarking
      • 9.2.12.4. Strategic initiatives
    • 9.2.13. Trinity Biotech
      • 9.2.13.1. Company overview
      • 9.2.13.2. Financial performance
      • 9.2.13.3. Product benchmarking
      • 9.2.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Lyme disease testing market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 5 North America Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 6 North America Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 8 U.S Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 9 U.S Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 10 U.S Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 12 Canada Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 13 Canada Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 14 Canada Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 16 Mexico Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 17 Mexico Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 18 Mexico Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe Lyme disease testing market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 22 Europe Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 23 Europe Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 25 Germany Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 26 Germany Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 27 Germany Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 29 UK Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 30 UK Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 31 UK Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 33 France Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 34 France Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 35 France Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 37 Italy Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 38 Italy Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 39 Italy Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 41 Spain Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 42 Spain Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 43 Spain Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 45 Denmark Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 46 Denmark Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 47 Denmark Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 49 Sweden Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 50 Sweden Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 51 Sweden Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 53 Norway Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 54 Norway Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 55 Norway Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Lyme disease testing market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 60 Asia Pacific Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 62 China Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 63 China Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 64 China Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 66 Japan Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 67 Japan Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 68 Japan Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 70 India Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 71 India Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 72 India Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 74 South Korea Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 75 South Korea Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 76 South Korea Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 78 Australia Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 79 Australia Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 80 Australia Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 82 Thailand Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 83 Thailand Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 84 Thailand Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Lyme disease testing market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 87 Latin America Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 88 Latin America Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 89 Latin America Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Brazil Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 92 Brazil Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 93 Brazil Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 95 Argentina Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 96 Argentina Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 97 Argentina Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA Lyme disease testing market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 100 MEA Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 101 MEA Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 102 MEA Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 105 South Africa Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 106 South Africa Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 113 UAE Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 114 UAE Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Lyme disease testing market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Lyme Disease Testing market: market outlook
  • Fig. 14 Lyme Disease Testing competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Lyme Disease Testing market driver impact
  • Fig. 18 Lyme Disease Testing market restraint impact
  • Fig. 19 Lyme Disease Testing market: Technology movement analysis
  • Fig. 20 Lyme Disease Testing market: Technology outlook and key takeaways
  • Fig. 21 IGRA Testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lyme Disease Testing market: Testing movement analysis
  • Fig. 24 Lyme Disease Testing market: Testing outlook and key takeaways
  • Fig. 25 Serological test market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 ELISA market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Western Blot market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Lymphocytic transformation test market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Urine Antigen Testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Immunofluorescent Staining market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Nucleic Acid Test market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Lyme Disease Testing market: Sample movement analysis
  • Fig. 33 Lyme Disease Testing market: Sample outlook and key takeaways
  • Fig. 34 Blood market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Urine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 CSF market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Lyme Disease Testing market: End Use movement analysis
  • Fig. 39 Lyme Disease Testing market: End Use outlook and key takeaways
  • Fig. 40 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Diagnostic Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Global Lyme Disease Testing market: Regional movement analysis
  • Fig. 44 Global Lyme Disease Testing market: Regional outlook and key takeaways
  • Fig. 45 Global Lyme Disease Testing market share and leading players
  • Fig. 46 North America, by country
  • Fig. 47 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 U.S key country dynamics
  • Fig. 49 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Canada key country dynamics
  • Fig. 51 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Mexico key country dynamics
  • Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 UK key country dynamics
  • Fig. 56 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Germany key country dynamics
  • Fig. 58 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 France key country dynamics
  • Fig. 60 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Italy key country dynamics
  • Fig. 62 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Spain key country dynamics
  • Fig. 64 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Denmark key country dynamics
  • Fig. 66 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Sweden key country dynamics
  • Fig. 68 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Norway key country dynamics
  • Fig. 70 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 China key country dynamics
  • Fig. 73 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Japan key country dynamics
  • Fig. 75 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 India key country dynamics
  • Fig. 77 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Thailand key country dynamics
  • Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 South Korea key country dynamics
  • Fig. 81 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Australia key country dynamics
  • Fig. 83 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Brazil key country dynamics
  • Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Argentina key country dynamics
  • Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 South Africa key country dynamics
  • Fig. 91 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Saudi Arabia key country dynamics
  • Fig. 93 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 UAE key country dynamics
  • Fig. 95 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Kuwait key country dynamics
  • Fig. 97 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Market share of key market players- Lyme Disease Testing market